

# EFPIA's Proposal for Coding and Identification of Pharmaceutical Products in Europe

From Vision to implementation

Jean-Marc Bobée – Sanofi Aventis Chair Steering Committee




GS1 Healthcare Conference – 31 October 2007

### The coding situation in Europe today


- Codification has evolved on a national basis, either voluntarily to facilitate product distribution, or compulsorily in response to some legal requirements.
- Only a handful of European countries use the internationally accepted EAN system managed by GS1; other countries have adopted their own product identification code.
- Bar Code symbology varies greatly from one country to another (the EAN 13 being the most widely used)
- National legal requirements governing codification are a growing trend throughout Europe aiming towards greater traceability requirements



### Current National Coding Systems across Europe



### Overview of National Codification Systems





# Why implement a unique coding solution?

- Need to improve patient safety at a European level and enhance the control of the supply chain
  - Dispensing and dosing errors risk
  - Reimbursement fraud & counterfeits cases increase
  - Lack of transparency of the supply chain/Repackaging
  - Difficulties in tracking and tracing medicines for efficient batch recall
- Fragmented supply chain in Europe with different coding schemes implemented or proposed by different Member States (⇒ 27 different Bollino in Europe ?)
  - Increase manufacturing complexity, production costs and supply chain differentiation across the European market
  - Individual systems are inefficient to protect European boarders

⇒ EFPIA's proposal for a standardised coding & identification of pharmaceuticals in Europe








The EFPIA concept on identification and coding of pharmaceutical products consists in two parts:

 The <u>harmonisation of pharmaceutical products codification</u> throughout Europe via the <u>implementation of a serialized Data</u> <u>Matrix</u> (ECC 200) on secondary packaging of all products sold in Europe

2. The <u>verification of pharmaceutical products</u> at their point of

dispensing









EFPIA proposal for harmonisation of pharmaceutical products codification throughout Europe:

- Implement a <u>Data Matrix ECC 200</u> barcode on all secondary packaging of pharmaceutical products sold in Europe
- Containing the 4 following pieces of information :
  - The manufacturer product code (14 digits)
     ⇒ GTIN" ('Global Trade Item Number') according to GS1 Standards
  - 2. a <u>unique</u> serial number (randomized 20 digits)
  - 3. the **expiry date** (6 digits yy/mm/dd)
  - 4. the **batch number** (10 alpha-numeric characters)



### GTIN Definition & Information Content of Datamatrix

- GTIN = Global Trade Item Number (= EAN.UCC14) = unit of sales
- The product code contains 14 digits = Indicator (1digit) + EAN 13
- This product code is unique throughout the world (GS1 codification)

Indi- cator	Company code (owner of the Market Authorisation)							Product number (1 à 99999)					Check digit
1	N	N	N	N	N	N	N	0	0	0	0	1	C

- Product information is coded in the Datamatrix using EAN-UCC 128 syntax
- Standard harmonized Application Identifiers (AI) are used to announce the type of information provided :
  - Al (01): identify the product code of the commercial unit
     (GTIN = 14 numeric digits)
  - Al (10): identify the batch number (10 alphanumeric digits)
  - Al (17): identify the expiry date (6 numeric digits YYMMDD)
  - Al (21): identify the serial number (20 numeric digits)



# Implementation of Data Matrix ECC 200 on line has engineering and information systems impacts

- Project specific to each pharmaceutical company EFPIA guidelines about technical aspects of Data Matrix implementation have been provided on 20 March 2007
- 5 technologies available for <u>data matrix printing/engraving</u> on packaging lines: continuous inkjet, Laser (C02 scribing), drop on demand, thermal inkjet and thermal transfer
- Data matrix codes are <u>read by imaging devices</u> (Charge Couple Devices video Cameras) which capture a picture and search for the locator pattern of the code. Then starts the decoding process
- Need to constitute an <u>internal company database</u> including all the serial numbers applied on products packs



# Example of serialized data matrix product






# Verification of pharmaceutical products

# Verification of pharmaceutical products will take place at the point of dispensing (pharmacy) and implies:

- Availability of company data (serial numbers) to health professionals (pharmacies, hospitals...) through a web specific professional network in order to verify the identity of the products (packs) to be delivered to patients
- Common professional project to the entire Pharma Industry







# Challenges & Key Questions

- 1. Harmonization of product codes
- Coding standards
- 3. System critical requirements
- 4. Obtaining support from key stakeholders
- 5. System governance model principles
- 6. Pilot country



# Harmonization of product codes

### EFPIA proposal for Coding Standards:

- Adopt preferentially the <u>GS1 standard "GTIN"</u> ('Global Trade Item Number'/14 digits) throughout Europe
- In case of existing national codes (different from a GTIN) accept as an interim solution the integration of the national code in a 13-digits structure compatible with GS1–128 syntax in order to read data matrix information in an harmonized way in Europe
  - ⇒ Pseudo GTIN concept (Example : CIP 13 in France) a.k.a 'Restricted Trade Item Number'



# **EFPIA** recommendation for pharmaceutical products coding in **EUROPE**

### EFPIA (2D Data matrix)

Manufacturer Product Code 14 digits [GTIN or pseudo GTIN]

Unique Serial Number 20 digits

Expiry Date 6 digits (yy/mm/dd)

Batch Number 10 alpha-numeric characters

GTIN: 12345678901234

Batch: A1C2E3G4I5 Ser 1234567890 Expiry: 07-2008 Num 1234567890



Coding Standards



GS1 Standards: Sq. Min: 24 x 24

**Rect. Min:** 16 x 48

Pixels/Cell: 8 No. of Char: 65 ECC: 200

**Text:**~5011234567890123421123456789012 34567890~d0291708120710A1C2E3G4I5~d

029



Size of data matrix code matters

Impact on speed of printing also a concern

It may be possible to fit the data into a new standard matrix of size 16 x 32

**Sq. Min:** 22 x 22

**Rect. Min:** 16 x 36

Pixels/Cell: 8
No. of Char: 54
ECC: 200

Text:~5311234567890123412345678 901234567890081207A1C2E3G4I5







# System Critical Requirements

### System Security

Most crucial element – need ultra secure system

### Data Segregation

 Stratified central database system - segregation by manufacturer, linking back to respective company product database

### System design

- the server design is likely to consist of clusters
- Integration into pharmacy system (software)

### Response time

under 1 second from the time of scanning

### System reliability/robustness

 Likely > 99.9%\_⇒ in case of system downtime, need store transaction on local system for verification at later stage



## Conditions for Stakeholders Support – Phase I

Customize EFPIA concept to national & european needs

### **Industry**

- Data matrix mass serialization
- Success factors:
  - Harmonized approach in Europe
  - Control at dispensing point
  - Shared system costs or value information in return

# Patient • Conti

Safety

### **Pharmacists**

- Control at dispensing point Success factors:
  - Seamless integration into pharmacy practice in Europe
  - Governance and management to be shared
  - Management of wholesalers' needs and expectations

### **Member States Health Authorities**

- Mandate codification and control at dispensing point
- <u>Success factors</u>: Traceability improvement + counterfeiting prevention
- Improve reimbursement system (avoid fraud & reduce complexity/costs)



# System Governance Model: Principles

- Central independent non-profit organization governed by stakeholders
- System will be self-financed through neutral release of sales information based on <u>regional brick data</u> in return (not individual pharmacy information)
- Stakeholders can organize themselves country by country (i.e. CIP/GERS model in France)



# Pilot Project – Country selection

#### Countries assessed so far:

#### Greece – rejected

- Complex and cumbersome political situation
- No data matrix but serialized vignette (linear barcodes/Sequential serial numbers)

#### Spain – still under consideration

- Parallel project for traceability ran by government need to secure crucial market
- Local industry keen to get involved
- Situation unclear with pharmacists
- Authorities appear to be supportive
- Timeline unclear

### Germany – under assessment

- Political opportunity Discussion of local stakeholders over revision of National product code (PZN)
- Industry/pharmacist/wholesaler appear keen to get involved
- Need further assessment of the environment

#### France – under assessment

- Data matrix already place
- Organisations already in place (CIP/GERS)
- General support from all parties (including authorities)



# **Project Timeline**



Development of concept EFPIA Vision

Preliminary stakeholder management

Internal Industry assessment Define User
Requirement
Specifications
(URS)

Project
evaluation
Contract
signed Sept 07

Assessment of countries for pilot projects

Release of URS by Melior Solutions

Selection of pilot country Open call for tender for technology services providers (Database/PILL management

Create expert group to review URS and prepare tender

Select technology
service provider
and
prepare
pilot experiment

Expert group to develop solution for governance model

Implementation
of pilot
experiment to
demonstrate
the feasibility of
the EFPIA
concept deployed in a
selected EU
country



### Conclusion

- The EFPIA project is a long-term project. It is ambitious but represents an <u>achievable</u>, <u>effective</u> and <u>efficient solution</u> for delivering much needed improvements in patient safety
- The project is a <u>concrete</u> response to various governments' proposals for specific national coding solutions
- The project is <u>scalable</u> allowing the extension to a full track & trace system in the future
- The project is expensive (But so is cost of non action)
- All stakeholders need to work together constructively to deliver real patient safety benefits
- Need to start a pilot ASAP to demonstrate feasibility & benefits



# Back up slides



## Benefits of a standardised coding system

- Harmonized and unique codification concept in Europe based on mass serialization
- More effective and efficient products recalls
- Improved traceability for pharmacy and hospital management systems allowing reduction of dispensing errors
- Prevention of counterfeit medicines
- Improved borders protections (customs control)
- Effective, efficient reimbursement system with lower administration cost and prevention of fraud (governments)
  - → More efficient and secured medicines supply chain
  - → Reduction in liability risks, meeting better duty of care
  - ⇒ Improved Patient safety



# Why Data Matrix ECC 200?

- Data matrix is a EAN.UCC (GS1) standard since July 2004
- Data matrix uses the international syntax EAN.UCC 128
- Data matrix is the smallest symbol for a given quantity of information
- Data matrix is robust: the Reed Solomon error correction system allow Data matrix reading even with a high level of code damage (information redundancy)
- Data matrix can be printed with technologies currently used in Pharmacy (thermal transfer, Inkjet, laser)
- Data matrix cost is very competitive (0.1 to 0.3 cents of €)



### The 2D Data matrix barcode: Key benefits

- Data matrix is the smallest code for a given quantity of information.
- It is robust (40% information redundancy) and highly cost competitive
- Data matrix will be mandatory in France on the 1st of January 2011 for each pharmaceutical packaging (product code+ batch n° + expiry date)
- Data matrix (ECC200) is the harmonized solution recommended by EFPIA for products identification in Europe (on secondary packaging)
  - Recommendation includes serialization, i.e. attribution of a unique number per box
  - In future, control of serial numbers at the dispensing point (Pharmacies & Hospitals) could protect patients from counterfeit

LOT ABC123 EXP 12JUN03 (01)0412345678901





# Data matrix (ECC 200)



(01) 3400930000122 (10) n°de lot (17) AAMMJJ

- The Data matrix symbol is a matrix made of black and white dots representing respectively 1 or 0
- Matrix can be square or rectangular
- Data are encoded in bytes and several additional bytes are added (redundancy) for errors detection and errors correction (in case of damage for example)



# Data matrix vs. RFID (unit of sales)

	Data Matrix	RFID
Ability to read at distance/No direct line of sight required?		<u>()</u>
Difficulty to modify / alter / copy the code content ?	<del>(</del>	
Readability robustness? (Interferences with metals/liquids) Efficiency of reading rates? (100% required)	$\odot$	
Business processes changes ?	$\odot$	
High speed tagging ? High volumes ?	<u>(-)</u>	
Volume of data to manage? Network complexity (EPC Global)	<u>(-)</u>	
Harmonization of Standards (EU /US/Asia) ?	( <del>:</del> )	
Privacy issues/objections/public concerns ?	<u>:</u>	
RFID Tag cost= 0.20 € to 0.40 € Serialized  Data Matrix cost = 0.002€ to 0.003 € (~100 times cheaper)		

### **RFID Assessment**

- Experience within the pharmaceutical industry (pilot projects) and other sectors have shown that the technology is not mature enough and is not able to meet all expectations of the industry for the time being.
- Indeed, a number of problems remain to be worked out, namely reliability of the technology, readability issue (interference with liquids and metals), high costs, but also lack of common standards as well as public concerns due to privacy issues.
- The adoption of a 2D system does not prevent the adoption of an RFID system at a latter stage nor does it represent a double cost. In fact, RFID offers significant benefits in terms of logistics management and would certainly be a natural progression of the system once the technology has matured.

